Drugs / SB257049
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT00360230 | Aug 2006 → Aug 2007 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02699099 | May 2017 → Mar 2018 | malaria | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SB257049 | “The purpose of this study is to assess the immunogenicity, safety, and reactogenicity of the SB257049 candidate malaria vaccine when co-administered with Vitamin A, measles,...” NCT02699099 ↗1“Healthy infants between 5 and 17 months of age at the time of first vaccination received 2 doses of SB257049 formulation 2 (F2) vaccine according to a 0, 1-month schedule...” NCT00360230 ↗ |
| Modality | Vaccine | “SB257049 formulation 2 (F2) vaccine” NCT00360230 ↗ |
| Route | Intramuscular | “administered intramuscularly (IM) in the left deltoid muscle” NCT00360230 ↗ |